In this episode of RhAPPcast, the official podcast of Rheumatology Advanced Practice Providers, host Amanda Mixon, PA-C, is joined by Audrey Gibson, PA-C, for part three of their special RhAPP Up series covering key psoriatic arthritis updates from the 2026 EULAR Congress.

They begin by discussing real-world evidence on long-term treatment persistence with advanced therapies in psoriatic arthritis, highlighting how different mechanisms of action compare over time. The conversation focuses on what persistence and discontinuation rates may reflect in clinical practice and how real-world data can help inform treatment decisions.

The episode also reviews a phase 2B study of a selective TYK2 inhibitor, exploring its effects on inflammatory biomarkers and clinical response in patients with active psoriatic arthritis. The discussion highlights how emerging biomarker research may one day help guide more personalized treatment selection and improve outcomes.

Whether you're a rheumatology provider, advanced practice provider (APP), or other healthcare professional, this episode offers practical insights into real-world treatment patterns, emerging targeted therapies, and the future potential of biomarker-driven precision medicine in psoriatic arthritis care.

Thank you for watching, be sure to explore the three-part ILD RhAPP Up Series, and stay tuned for our upcoming Osteoporosis Abstract Reviews.

In this episode of RhAPPcast, the official podcast of Rheumatology Advanced Practice Providers, host Amanda Mixon, PA-C, is joined by Audrey Gibson, PA-C, for part two of their special RhAPP Up series covering key psoriatic arthritis updates from the 2026 EULAR Congress.

They discuss new long-term data highlighting the durability of response with emerging therapies in psoriatic arthritis, including how patients who respond early may be able to maintain disease control over several years. The conversation focuses on what sustained efficacy means for real-world treatment decisions and long-term disease management.

The episode also reviews subgroup data from a phase 3 study of an IL-23–targeting therapy, showing consistent improvements in joint symptoms and inhibition of structural damage progression across a range of patient types. The discussion highlights the importance of early inflammation control and its role in reducing long-term joint damage.

Whether you're a rheumatology provider, advanced practice provider (APP), or other healthcare professional, this episode offers practical insights into long-term treatment outcomes, emerging biologic therapies, and key factors that may influence therapy selection in psoriatic arthritis care.

Stay tuned for part three of the RhAPP Up series and visit the Content Rheum to stay up to date with the latest clinical insights in rheumatologic care.

In this episode of RhAPPcast, the official podcast of Rheumatology Advanced Practice Providers, host Amanda Mixon, PA-C, is joined by Audrey Gibson, PA-C, as they kick off the first episode of a special three-part RhAPP Up series focused on key psoriatic arthritis updates from the 2026 EULAR Congress.

They discuss several key abstracts from the meeting, including a head-to-head trial comparing two different therapeutic approaches in active psoriatic arthritis and what the results may mean for treatment decisions in clinical practice. The conversation highlights how new data may help guide therapy selection and improve patient care.

The episode also reviews emerging data on a novel IL-17A inhibitor and its impact on patient-reported outcomes, including pain, fatigue, physical function, and quality of life. The conversation emphasizes the importance of aligning treatment goals with what matters most to patients, not just traditional clinical endpoints.

Whether you're a rheumatology provider, advanced practice provider (APP), or other healthcare professional, this episode offers practical insights into evolving psoriatic arthritis treatment strategies, emerging biologic therapies, and the growing emphasis on precision medicine in inflammatory arthritis care.

Stay tuned for Part 2 of the RhAPP Up series and visit the Content Rheum to stay up to date with the latest clinical insights in rheumatologic care.

In this episode of RhAPPcast, the official podcast of Rheumatology Advanced Practice Providers, host Amanda Mixon, PA-C, and guest Jessica Glennie, CNP, conclude their 2026 EULAR ILD RhAPP Up Series with a review of important new research on rheumatoid arthritis-associated interstitial lung disease (RA-ILD) and progressive pulmonary fibrosis (PPF).

The discussion examines long-term data showing that interstitial lung disease can develop in patients with rheumatoid arthritis despite effective disease control, reinforcing the importance of ongoing screening and pulmonary monitoring. The episode also highlights new findings on an emerging antifibrotic therapy, including its potential to slow lung function decline, reduce respiratory complications, and improve outcomes for patients with autoimmune-related lung disease.

Whether you're a rheumatology provider, advanced practice provider (APP), or other healthcare professional, this episode offers practical insights into identifying patients at risk for ILD, the value of early detection, and advances in the treatment of progressive pulmonary fibrosis.

Stay tuned for new episodes highlighting the Osteoporosis and PsA Abstracts from EULAR 2026. Visit the Content Rheum and RhAPP ACE app for more rheumatology education.

In this episode of RhAPPcast, the official podcast of Rheumatology Advanced Practice Providers, host Amanda Mixon, PA-C, welcomes Jessica Glennie, CNP, to continue their 2026 EULAR ILD RhAPP Up series by reviewing the latest research on systemic sclerosis-associated interstitial lung disease (SSc-ILD) and progressive pulmonary fibrosis (PPF).

The discussion highlights new real-world data showing that many patients with early SSc-ILD maintain stable lung function when closely monitored and treated appropriately. The episode also explores the safety and tolerability of an emerging antifibrotic therapy, reviewing its potential role in slowing disease progression while offering a favorable side effect profile for patients with autoimmune-related lung disease.

Whether you're a rheumatology provider, advanced practice provider (APP), or other healthcare professional, this episode delivers practical insights into early disease monitoring, evolving treatment options, and strategies to help improve long-term outcomes for patients with ILD.

Stay tuned for Part 3 and visit the Content Rheum to stay up to date with the latest clinical insights in rheumatologic care.

In this episode of RhAPPcast, the official podcast of Rheumatology Advanced Practice Providers, host Amanda Mixon, PA-C, is joined by Jessica Glennie, CNP, as they discuss key interstitial lung disease (ILD) updates from the 2026 EULAR Congress in the first episode of a special three-part RhAPP Up series.

They explore the healthcare and financial impact of connective tissue disease-associated ILD (CTD-ILD), highlighting why early diagnosis and treatment are so important for improving patient outcomes and reducing long-term costs. The episode also reviews emerging research on a potential new therapy for systemic sclerosis that may target multiple aspects of the disease and help slow its progression.

Whether you're a rheumatology provider, advanced practice provider (APP), or other healthcare professional, this episode provides practical insights into the latest ILD research, evolving treatment strategies, and the value of early, multidisciplinary care.

Stay tuned for Part 2 and visit the Content Rheum to stay up to date with the latest clinical insights in rheumatologic care.

Stay ahead of the latest advancements in rheumatology with this in-depth RhAPPcast episode exploring TYK2 inhibition and its expanding role in immune-mediated diseases. Hosted by Amanda Mixon, PA-C, this episode features expert insights from Danielle Gatti-Palumbo, PharmD, and Jennifer Mylod, DNP, as they break down the science behind TYK2 signaling within the JAK-STAT pathway and its clinical relevance in conditions like psoriatic arthritis, systemic lupus erythematosus (SLE), and Sjögren’s syndrome.

Learn how TYK2 inhibitors—such as deucravacitinib—are reshaping treatment strategies by targeting key cytokines like IL-12, IL-23, and type 1 interferons, offering a potentially effective oral alternative with a differentiated safety profile compared to traditional JAK inhibitors. The discussion highlights pivotal clinical trials including POETYK PSO-1, POETYK PSO-2, and emerging phase 3 data in psoriatic arthritis, as well as promising findings from the PAISLEY trial in lupus. Additionally, the episode explores the unmet need in Sjögren’s syndrome and how evolving trial designs and outcome measures may pave the way for future targeted therapies.

Whether you're a rheumatology provider, advanced practice provider (APP), or healthcare professional interested in autoimmune disease management, this episode delivers key clinical insights, trial data, and future considerations shaping the next wave of immunomodulatory therapies. For more rheumatology education, check out the RhAPP Content Rheum or download the RhAPP ACE app.

Explore the latest evidence in obesity management in this journal club review of the SURMOUNT-5 clinical trial, presented by Bharati Bhardwaja, PharmD, from Kaiser Permanente Colorado. This video breaks down a Phase 3b randomized trial comparing tirzepatide and semaglutide in adults with obesity without type 2 diabetes, highlighting key efficacy and safety outcomes over 72 weeks.

Learn how tirzepatide demonstrated superior weight loss compared to semaglutide, achieving an average 20.2% reduction in body weight versus 13.7%, along with significantly greater reductions in waist circumference. The discussion also reviews clinically meaningful weight loss thresholds, showing that more patients on tirzepatide achieved ≥10%, ≥15%, ≥20%, and even ≥30% weight reduction. Safety findings are also covered, including common gastrointestinal side effects such as nausea, diarrhea, constipation, and vomiting, as well as considerations during dose escalation.

Designed for healthcare professionals and clinicians managing obesity and metabolic disease, this video provides a clear, evidence-based comparison of two leading therapies, offering practical insights to guide treatment decisions and optimize patient outcomes in obesity care. For more expert-led education, visit the Content Rheum and stay up to date with the latest clinical insights in rheumatologic care.